Vaccines and Public Health
Adult immunization rates are falling short of national targets. Learn how global, federal, and state policies affect vaccination uptake. Leverage our findings to guide your strategies. Rely on our expertise commercializing novel and therapeutic vaccines.
50-State Comparison of Medicaid Adult Vaccine Provider Reimbursement
A new Avalere analysis identified variability in Medicaid physician office, pharmacy, and Federally Qualified Health Centers vaccine reimbursement policies.
IRA Policy Will Fill Gaps in Medicaid Vaccine Coverage for Adults
Avalere identified 19 states that must change their Medicaid vaccine policies to comply with the IRA’s requirement that states cover all recommended vaccines without cost sharing.
Interview: RSV Prevention, Part IV: Immunocompromised Populations
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
Video: RSV Prevention, Part IV: Immunocompromised Populations
Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.
Interview: RSV Prevention, Part III: Older Adult Vaccination
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.
Video: RSV Prevention, Part III: Older Adult Vaccination
Tune into the third episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the future of RSV among older adults.
Video: RSV Prevention, Part II: Pediatric Vaccines and Maternal immunization
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
Interview: RSV Prevention, Part II: Pediatric Vaccines and Maternal immunization
Tune into the second episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss RSV prevention products currently in development, specifically maternal immunizations and pediatric vaccines.
Video: RSV Prevention, Part I: Pediatric Monoclonal Antibodies
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
Interview: RSV Prevention, Part I: Pediatric Monoclonal Antibodies
Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.
Navigating the Road to RSV Prevention
Numerous novel respiratory syncytial virus (RSV) preventive products, including vaccines and monoclonal antibodies (mAbs), are in late-stage clinical development. Consequently, the RSV prevention landscape is expected to transform in the coming years. Adequate preparation to incorporate the use of these new tools should consider the regulatory and recommendation pathways and their implications for coverage and reimbursement.
Several Changes to Adult Vaccine Access Enacted Through IRA
The IRA will expand adult vaccine access by mandating coverage without cost sharing for all adult vaccines in Medicare Part D and Medicaid.
Vaccine Incentives for Providers Would Change Due to 2 MPFS Proposals
CMS is proposing to update vaccine administration reimbursement rates annually and make changes to adult vaccination quality metrics, beginning in 2023.
Comparing Medicare FFS Pneumococcal Vaccination Rates in 2019 and 2020
A new study from Avalere analyzes age, race and ethnicity, and Medicare-Medicaid dual-eligibility status of Medicare Fee-For-Service (FFS) beneficiaries with pneumococcal vaccine claims in 2019 and 2020.
Addressing Climate Change Impacts on Health
As climate change continues to alter the patterns of everyday life, healthcare stakeholders should consider strategies to prevent and mitigate negative environmental contributions and proactively address the impacts of climate change on health outcomes, health equity, and healthcare costs.
Microarray Patches Could Improve Pandemic Vaccination
The rollout of COVID-19 vaccines highlights the need for continued innovation in how vaccines are delivered.
Midlife Prevention of Alzheimer’s Disease
Although Alzheimer’s disease has no known cure, recent evidence points to several advancements that may enhance the understanding of the progression of the disease.
Declines in Routine Adult and Teen Vaccinations Continued in 2021
Updated Avalere analysis shows that routine immunization continued to lag in 2021 below pre-pandemic levels, highlighting the continuing effect of COVID-19 on routine vaccination.
Avalere Research Highlights Alternative Settings for Vaccination
The CDC recommends HBV vaccinations for persons with a history of current or recent injection drug use, but uptake remains low. Avalere research shows an opportunity to leverage alternative care settings to address the growing rates of HBV infection.
Impact of Removing Part D Vaccine Cost-Sharing on the Federal Budget
The COVID-19 pandemic has brought renewed attention and urgency to mitigating access barriers to recommended vaccines.